[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Giuliante F, Sarno G, Ardito F, Pierconti F: Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge. Tumori; 2009 May-Jun;95(3):374-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic leiomyosarcoma in a young man after Hodgkin's disease: diagnostic pitfalls and therapeutic challenge.
  • BACKGROUND: Primary leiomyosarcoma of the liver is a rare tumor whose development patterns are unsatisfactorily known.
  • PATIENT CASE: A 26-year-old male patient with a previous history of radiochemotherapy treatment for Hodgkin's lymphoma was referred to our unit with a histological and radiological diagnosis of primary hepatic leiomyosarcoma.
  • Six months before referral, in a workup for hypertension, a CT scan of the abdomen had shown a 2.5-cm lesion in liver segment VII, which was interpreted as an angioma.
  • Shortly before referral the lesion had grown to 7.8 cm, associated with two smaller lesions in segments VIII and III, and a diagnosis of hepatic leiomyosarcoma was made at biopsy.
  • This was followed by rapid progression of the disease, in spite of transient stabilization under gemcitabine treatment.
  • Octreotide was also administered after the detection of elevated chromogranin A in serum.
  • The patient died 25 months after liver resection.
  • CONCLUSIONS: The challenges and peculiarities of this case are related to the rarity of the tumor, its accidental discovery without immediate suspicion of its nature, its very aggressive behavior that was only partly controlled by chemotherapy, and the unusual expression of a neuroendocrine phenotypic feature with high serum chromogranin A levels.
  • [MeSH-major] Hodgkin Disease. Leiomyosarcoma. Liver Neoplasms. Neoplasms, Second Primary
  • [MeSH-minor] Adult. Fatal Outcome. Hepatectomy. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688980.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Lang H, Nussbaum KT, Kaudel P, Frühauf N, Flemming P, Raab R: Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period. Ann Surg; 2000 Apr;231(4):500-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period.
  • OBJECTIVE: To describe a large single-center experience with hepatic resection for metastatic leiomyosarcoma.
  • SUMMARY BACKGROUND DATA: Liver resection is the treatment of choice for hepatic metastases from colorectal carcinoma.
  • In contrast, the role of liver resection for hepatic metastases from leiomyosarcoma has not been defined.
  • METHODS: The records of 26 patients who between 1982 and 1996 underwent a total of 34 liver resections for hepatic metastases from leiomyosarcoma were reviewed.
  • There were 23 first, 9 second, and 2 third liver resections.
  • RESULTS: In the 23 first liver resections, there were 15 R0, 3 R1, and 5 R2 resections.
  • In 10 patients with extrahepatic tumor at the time of the first liver resection, 6 R0 and 4 R2 resections were achieved.
  • After repeat liver resection, the median survival was 31 months (range 5-51 months); after R0 resection, median survival was 31 months and after R1/2 resection it was 28 months.
  • There was no 5-year survivor in the overall group after repeat liver resection.
  • CONCLUSIONS: Despite frequent tumor recurrence, the long-term outcome after liver resection for hepatic metastases from leiomyosarcoma is superior to that after chemotherapy and chemoembolization.
  • Although survival after tumor debulking also seems to be more favorable than after nonoperative therapy, these data indicate that only an R0 resection offers the chance of long-term survival.
  • The presence of extrahepatic tumor should not be considered a contraindication to liver resection if complete removal of all tumorous masses appears possible.
  • In selected cases of intrahepatic tumor recurrence, even repeated liver resection might be worthwhile.
  • In view of the poor results of chemoembolization and chemotherapy in hepatic metastases from leiomyosarcoma, liver resection should be attempted whenever possible.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1968 Jul;127(1):1-11 [5657778.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1423-7 [9782030.001]
  • [Cites] Surgery. 1982 Oct;92(4):610-4 [6289486.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):239-46 [3629438.001]
  • [Cites] Langenbecks Arch Chir. 1988;373(2):122-6 [3287072.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):23-35 [2839123.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1261-6; discussion 1266-8 [2171452.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] Surg Gynecol Obstet. 1991 Dec;173(6):454-60 [1948602.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):766-70 [8392904.001]
  • [Cites] J Am Coll Surg. 1995 Jan;180(1):1-9 [8000645.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):36-42; discussion 42-3 [7817996.001]
  • [Cites] Langenbecks Arch Chir. 1994;379(6):321-8 [7845156.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2083-8 [7697597.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):72-5 [7740813.001]
  • [Cites] Chirurg. 1996 Feb;67(2):161-8 [8881214.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Curr Probl Surg. 1981 Mar;18(3):157-202 [7016459.001]
  • (PMID = 10749609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Other-IDs] NLM/ PMC1421024
  •  go-up   go-down


3. Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, Goto T: Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med; 2005 Feb;44(2):114-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.
  • We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after previous failed extensive therapy, including multiple surgeries and hepatic artery embolization.
  • Within a few months of starting administration of imatinib mesylate, the patient exhibited a clinical response with grade 3 neutropenia, when pulmonary tuberculosis developed.
  • A c-kit mutation in exon 11 was detected only in metastatic liver specimens.
  • It is unclear whether or not pulmonary tuberculosis may be induced by imatinib mesylate treatment, but caution is warranted in immunocompromised GIST patients.
  • This is the first report of tuberculosis associated with neutropenia during imatinib mesylate treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Stromal Tumors / complications. Jejunal Neoplasms / complications. Leiomyosarcoma / complications. Piperazines / adverse effects. Pyrimidines / adverse effects. Tuberculosis, Pulmonary / complications
  • [MeSH-minor] Administration, Oral. Antitubercular Agents / therapeutic use. Benzamides. Combined Modality Therapy. Digestive System Surgical Procedures. Fatal Outcome. Humans. Imatinib Mesylate. Laparotomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / complications. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750270.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


Advertisement
4. Marcheix B, Dambrin C, Muscari F, Joseph-Hein K, Guimbaud R, Otal P: [Leiomyosarcoma of the inferior vena cava]. J Chir (Paris); 2003 Jun;140(3):140-8
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leiomyosarcoma of the inferior vena cava].
  • Leiomyosarcoma of the inferior vena cava is a rare tumor of mesenchymal origin most commonly found in women.
  • Imagery with ultrasound, CT, or MRI may strongly suggest the diagnosis, but it can only be confirmed by histologic examination of tissue obtained pre or intra-operatively.
  • Radical surgical resection is the only treatment which offers any hope for prolonged survival.
  • Progress in the techniques of hepatectomy and liver transplantation have allowed the experienced surgeon to undertake the removal of retrohepatic lesions once considered unresectable.
  • High-lying lesions adjacent to the hepatic veins or with thrombus extending into the proximal vena cava may require extracorporeal circulation with or without profound hypothermic circulatory arrest.
  • The efficacy of chemotherapy, whether pre-operative for inaccessible tumors or post-operative for incompletely resected or recurrent tumor, is poorly defined and very limited.
  • [MeSH-major] Leiomyosarcoma. Vascular Neoplasms. Vena Cava, Inferior
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12910211.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 48
  •  go-up   go-down


5. Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW: Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol; 2008 Mar;18(3):468-76
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
  • To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy.
  • Treated tumor entities were colorectal carcinoma (CRC) (n = 12), breast cancer (BC) (n = 12), cholangiocarcinoma (CCC) (n = 10), pancreatic (n = 4), ovarian (n = 3), gastric, cervical, papillary (each n = 2), prostate, esophageal carcinoma, leiomyosarcoma (each n = 1), cancer of unknown primacy (CUP) (n = 5).
  • All patients tolerated the treatment well without any major side effects or complications.
  • HIC with gemcitabine/mitomycin is a safe, minimally invasive, palliative treatment for hepatic metastases that are progressive under systemic chemotherapy.
  • The treatment yields respectable tumor control rates in CRC and BC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Breast Neoplasms / pathology. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Oncology. 2005;69 Suppl 3:17-24 [16301832.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 16;80(2):84-9 [3278123.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Eur J Surg Oncol. 2000 Apr;26(3):209-12 [10753531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23 (22):4888-96 [16009951.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):353-61 [15758131.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):1025-34 [16944163.001]
  • [Cites] Acta Oncol. 2003;42(4):263-75 [12899497.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Eur J Surg Oncol. 2005 Nov;31(9):932-41 [15979268.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Zentralbl Chir. 1995;120(10):786-90 [7502593.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):97-101 [16028279.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):745-55 [16858591.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):53-62 [16319993.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):42-8 [11750151.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4 [8137476.001]
  • [Cites] Ther Umsch. 2006 Apr;63(4):255-61 [16689456.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4881-7 [16009952.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):922-7 [16822644.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):26-31; discussion 32 [8289448.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2203-6 [2529960.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11 Suppl):131-5 [8953600.001]
  • [Cites] Recent Results Cancer Res. 1983;86:1-12 [6647987.001]
  • [Cites] Z Gastroenterol. 2006 Jul;44(7):587-98 [16823700.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):23-7 [10073147.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):167-70 [15901375.001]
  • [Cites] Zentralbl Chir. 1998;123 Suppl 5:159-61 [10063604.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:20-9 [16368868.001]
  • [Cites] Cancer Treat Rep. 1980 Jan;64(1):31-40 [6155210.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):781-7 [15379811.001]
  • (PMID = 17938935.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


6. Liang X, Xiao-Min S, Jiang-Ping X, Jie-Yu Y, Xiao-Jun Z, Zhi-Ren F, Guo-Shan D, Rui-Dong L: Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures. Med Oncol; 2010 Dec;27(4):1269-72
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures.
  • Primary hepatic leiomyosarcoma (PHL), a malignant mesenchymal tumor of myogenic origin, is exceedingly rare.
  • Patients may be afflicted with a wide spectrum of nonspecific symptoms, and most of the laboratory data are unhelpful to diagnosis.
  • Here, we report a 44-year-old woman with anorexia and right upper quadrant pain who was diagnosed as having malignant hepatic tumor within the Milan criteria and treated by orthotopic liver transplantation (OLT), the pathologic diagnosis of PHL was made by postoperative immunohistochemical study.
  • She underwent six courses of intravenous chemotherapy and enjoyed a 14-month tumor recurrence-free survival until the lymph node metastasis was detected, then we switched the tacrolimus to sirolimus and the patient survived for 20 months additionally.
  • The diagnostic and therapeutic features of PHL are also discussed by reviewing the literatures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunosuppressive Agents / therapeutic use. Leiomyosarcoma / therapy. Liver Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] Eur Radiol. 2008 Oct;18(10 ):2196-205 [18463872.001]
  • [Cites] Surg Today. 1999;29(1):67-70 [9934835.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Am J Transplant. 2006 Feb;6(2):392-7 [16426326.001]
  • [Cites] Gastroenterol Clin Biol. 1993;17(3):218-22 [8330697.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):485-97 [12916465.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1391-6 [17315167.001]
  • [Cites] Dig Dis Sci. 2003 Apr;48(4):677-82 [12741455.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):817-26 [17527068.001]
  • [Cites] Ital J Gastroenterol. 1996 Feb-Mar;28(2):98-101 [8782003.001]
  • [Cites] J Submicrosc Cytol Pathol. 1991 Oct;23(4):643-7 [1764691.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] World J Surg. 2009 Nov;33(11):2420-6 [19693632.001]
  • [Cites] Pediatr Transplant. 2001 Oct;5(5):365-9 [11560757.001]
  • [Cites] Eur J Radiol. 1995 Mar;19(3):177-82 [7601167.001]
  • (PMID = 19997990.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


7. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH: Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res; 2008 Jun 1;14(11):3477-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
  • EXPERIMENTAL DESIGN: Patients with advanced or metastatic cancer refractory to standard therapy were eligible.
  • Mainly moderate gastrointestinal toxicities occurred except for one patient who died after experiencing grade 4 hepatic failure during cycle two.
  • One patient with a leiomyosarcoma had stable disease during 2 years and 7 months.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacokinetics. Deoxycytidine / analogs & derivatives. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Area Under Curve. Cell Proliferation / drug effects. Drug Administration Schedule. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. T-Lymphocytes / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18519780.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res; 2002 Jan;8(1):75-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevations in hepatic transaminases were common at ET-743 dose levels > or =216 microg/m(2)/day, resolved rapidly, and were never dose limiting nor cumulative.
  • Antitumor activity was noted in three patients with leiomyosarcoma and primary peritoneal and ovarian carcinomas.
  • The pharmacokinetics of ET-743 were dose independent, and drug accumulation over the 5 days of treatment was modest, with the ratio of the area under the plasma-versus-time curve on day 5 to that on day 1 averaging 2.05.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine Transaminase / metabolism. Area Under Curve. Aspartate Aminotransferases / metabolism. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged. Tetrahydroisoquinolines. Time Factors. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801542.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR01346
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


9. Bonnet S, Eggenspieler P, Vedrine L, Camparo P, Baranger B: [Leiomyosarcoma of the middle segment of the inferior vena cava: tactical problems raised by renal and caval revascularisation]. J Mal Vasc; 2006 May;31(2):79-84
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leiomyosarcoma of the middle segment of the inferior vena cava: tactical problems raised by renal and caval revascularisation].
  • [Transliterated title] Léiomyosarcome du segment moyen de la veine cave inférieure: problèmes tactiques soulevés par la revascularisation cave et rénale.
  • INTRODUCTION: Leiomyosarcoma of the inferior vena cava is mesenchymal tumor accounting for 95% of primary tumors of the vena cava.
  • Characteristic features include late invasion of adjacent structures and metastases, and delayed diagnosis.
  • OBSERVATION: We report a case of inferior vena cava (IVC) leiomyosarcoma (LMS) found in a 53 year-old man who complained of abdominal pain.
  • Morphologic exams found a very large polycyclic mass in the inferior vena cava involving the middle segment of the vena cava extending from the renal veins to the hepatic veins.
  • Pathological examination documented a grade II leiomyosarcoma of the inferior vena cava and the patient was given adjuvant chemotherapy (anthracycline).
  • [MeSH-major] Kidney / blood supply. Leiomyosarcoma / diagnosis. Vascular Neoplasms / diagnosis. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733439.001).
  • [ISSN] 0398-0499
  • [Journal-full-title] Journal des maladies vasculaires
  • [ISO-abbreviation] J Mal Vasc
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Khabir A, Boudawara T, Ayadi L, Kharrat M, Kharrat M, Beyrouti I, Jlidi R: [Epithelioid bilateral ovarian leiomyosarcoma: a study]. Ann Pathol; 2003 Feb;23(1):47-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid bilateral ovarian leiomyosarcoma: a study].
  • [Transliterated title] Léiomyosarcome ovarien bilatéral de type épithélioïde: une observation.
  • Primary ovarian leiomyosarcoma is extremely rare and generally affects post menopausal women.
  • Its histogenesis is not clear its prognosis seems to be improved by radical surgery and adjuvant therapy.
  • A diagnosis of bilateral ovarian epithelioid leiomyosarcoma was made on pathological examination with immunohistochemistry.
  • Adjuvant chemotherapy was given.
  • After 3 months of follow up, abdominal sonography revealed a peritoneal recurrent tumor with hepatic metastasis.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Immunohistochemistry. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Menopause. Middle Aged. Ovariectomy. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12743499.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Dew J, Hansen K, Hammon J, McCoy T, Levine EA, Shen P: Leiomyosarcoma of the inferior vena cava: surgical management and clinical results. Am Surg; 2005 Jun;71(6):497-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: surgical management and clinical results.
  • Leiomyosarcoma of the inferior vena cava (IVC) is a rare lesion with less than 300 cases reported.
  • From August 1984 to June 2004, eight patients with leiomyosarcoma of the IVC were treated at our institution.
  • Tumor location was between the renal and iliac veins (low) (n = 4, 50%), between the hepatic and renal veins (middle) (n = 3, 38%), and above the hepatic veins with right atrial extension (high) (n = 1, 12%).
  • One patient is currently receiving adjuvant chemotherapy.
  • Four patients received chemotherapy after recurrence, and one received palliative radiation therapy as well.
  • The type of IVC reconstruction had no effect on survival (P = 0.22).
  • Recurrence was discovered in four patients (50%) at a median time of 14 months.
  • Resection of leiomyosarcoma of the IVC should be attempted whenever feasible.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation / methods. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Vascular Surgical Procedures / methods

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044929.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Daylami R, Amiri A, Goldsmith B, Troppmann C, Schneider PD, Khatri VP: Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection? J Am Coll Surg; 2010 Feb;210(2):185-90
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection?
  • BACKGROUND: Leiomyosarcomas of the inferior vena cava represent a rare form of soft-tissue sarcomas.
  • Questions about necessity of multimodality therapy and IVC reconstruction remain.
  • Lower-extremity edema developed in 3 patients (50%), but this was well tolerated and did not lead to any long-term sequelae.
  • Pulmonary metastasis developed postoperatively in 1 patient (17%) and was successfully treated with chemotherapy and metastectomy.
  • Acute renal failure developed in 3 patients, but all recovered full function.
  • Chylous leak developed in 2 patients (34%).
  • CONCLUSIONS: Leiomyosarcoma of the IVC is a treatable malignancy.
  • Reconstruction of the IVC is not necessary for resection of tumors below the level of the hepatic veins in most if not all cases.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adrenalectomy. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Nephrectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Surg. 2010 Jul;211(1):145-6 [20610268.001]
  • (PMID = 20113938.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Takahashi T, Sakamoto J, Kosaka S: [Metastatic lung tumor from uterine leiomyosarcoma; report of a case]. Kyobu Geka; 2008 Jul;61(7):595-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic lung tumor from uterine leiomyosarcoma; report of a case].
  • We herein present a case of metastatic pulmonary tumor derived from endometrial leiomyosarcoma She had undergone hysterectomy for leiomyosarcoma.
  • About 10 years after the hysterectomy, metastatic hepatic tumors and peritoneal dissemination were pointed out.
  • Following chemotherapy of cisplatin, ifomide and pirarubicine, right hepatectomy was performed.
  • Postoperative chemotherapy was performed with the same regimen as previously performed.
  • Careful follow up after the surgery for the uterine leiomyosarcoma is recommended because metastatic leiomyosarcoma possibly appears even after a long interval, and its progress can be so intensive that adjuvant chemotherapy is necessary if it can not be treated surgically alone.
  • [MeSH-major] Endometrial Neoplasms / pathology. Leiomyosarcoma / pathology. Leiomyosarcoma / secondary. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616110.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Brichard B, Smets F, Sokal E, Clapuyt P, Vermylen C, Cornu G, Rahier J, Otte JB: Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation. Pediatr Transplant; 2001 Oct;5(5):365-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
  • We report the case of a child who developed, 2 yr after orthotopic liver transplantation (OLTx) for biliary atresia, a multi-focal hepatic tumor with lymphonodular metastases, identified as an Epstein-Barr virus (EBV)-associated leiomyosarcoma.
  • Chemotherapy was given without tumor response.
  • At the present time, 12 yr after the discovery of the first hepatic lesions, the patient is alive and completely symptom-free, the abdominal masses are stable, and liver function tests are completely normal.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Leiomyosarcoma / virology. Liver Neoplasms / virology. Liver Transplantation / immunology. Postoperative Complications / immunology


15. Al-Rikabi A, Hussain AA, Buchler M, Al-Muzrakchi A, Jyothi CR: Primary leiomyosarcoma of the inferior vena cava: report of a case diagnosed by fine needle aspiration cytology and confirmed by histopathologic examination. Acta Cytol; 2007 May-Jun;51(3):477-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the inferior vena cava: report of a case diagnosed by fine needle aspiration cytology and confirmed by histopathologic examination.
  • BACKGROUND: Leiomyosarcoma is a malignant neoplasm and can originate within major abdominal veins, including the inferior venacava (IVC).
  • CASE: A 45-year-old woman presented with upper abdominal pain and a mass lesion in the liver and within the lumen of the IVC.
  • A diagnosis of primary leiomyosarcoma of the IVC was made by using imaging techniques,fine needle aspiration cytology and histopathologic examination of the resected specimen.
  • CONCLUSION: In patients presenting with vague upper abdominal pain and radiologic features of a hepatic mass extending to major veins, the rare possibility of primary leiomyosarcoma of the IVC shoald he considered and investigated by both fine needle aspiration cytology and intraoperative histology.
  • Early surgical intervention and/or postoperative chemotherapy and radiotherapy are associated with improved survival.
  • [MeSH-major] Leiomyosarcoma / pathology. Vascular Neoplasms / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Humans. Middle Aged. Preoperative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536560.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gallup DG, Blessing JA, Andersen W, Morgan MA, Gynecologic Oncology Group Study: Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol; 2003 Apr;89(1):48-51
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
  • OBJECTIVE: The purpose of this phase II trial was to evaluate the efficacy of intravenous paclitaxel in patients with recurrent or advanced leiomyosarcoma of the uterus.
  • METHODS: To be eligible, patients with recurrent or persistent leiomyosarcoma of the uterus were to have measurable disease not previously treated with paclitaxel and adequate hematologic (WBC >or=3000/microl, platelet count >or=100000/microl), renal (serum creatinine <or=2.0 mg%), and hepatic (bilirubin <or= 1.5 x institutional normal) functions.
  • Fifteen had prior irradiation and 39 had prior chemotherapy.
  • No grade 4 thrombocytopenia was reported and no deaths were attributable to therapy.
  • CONCLUSIONS: Although toxicity was minimal, this regimen demonstrated modest activity in patients with previously treated advanced or recurrent leiomyosarcoma of the uterus.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694653.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / CA37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Smith HO, Blessing JA, Vaccarello L: Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2002 Jan;84(1):140-4
Hazardous Substances Data Bank. TRIMETREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus.
  • METHODS: Eligibility was restricted to patients with measurable disease who had received no more than one prior chemotherapy regimen, who had adequate bone marrow, renal, and hepatic function, and who had recovered from previous therapy.
  • Prior therapy included radiation (7 patients) and/or chemotherapy (10 patients).
  • Toxicities were mild to moderate with no treatment-related deaths.
  • CONCLUSION: Although toxicity is acceptable, trimetrexate at this dose and schedule is ineffective therapy for patients with recurrent leiomyosarcoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trimetrexate / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11748990.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; UPN4ITI8T4 / Trimetrexate
  •  go-up   go-down


18. Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group: Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol; 2005 Mar;96(3):749-52
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
  • OBJECTIVE: This is a phase II group-wide study of liposomal doxorubicin chemotherapy in patients with advanced or recurrent uterine leiomyosarcomas.
  • METHODS: Patients with histologically confirmed persistent or recurrent leiomyosarcomas of the uterus with documented disease progression after appropriate local therapy were invited to participate in this study.
  • Bidimensionally measurable disease, GOG performance status of 0, 1, or 2 (Karnofsky 80-100) was required; all patients must have failed local therapeutic measures and be considered incurable.
  • Other eligibility criteria included adequate hepatic, renal, and hematologic function.
  • Patients were ineligible if they had received previous chemotherapy or had other noncutaneous malignancies.
  • Three patients were determined ineligible because of wrong pathological cell type or inadequate pathology information and one was inevaluable for lack of data.
  • Two patients developed grade 3 and one patient developed grade 4 cardiovascular adverse events, not necessarily drug related.
  • There were seven cases of grade 3 or 4 gastrointestinal toxicity and two patients developed grade 3 dermatologic toxicity.
  • CONCLUSION: The dose and schedule of liposomal doxorubicin employed in this trial showed no advantage over historical results with doxorubicin in the treatment of uterine leiomyosarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721421.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J: Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol; 2002 Jun;85(3):507-10
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
  • OBJECTIVE: Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease.
  • METHODS: Patients with histologically confirmed uterine leiomyosarcoma who had not previously received cytotoxic drugs were considered for participation in this clinical trial.
  • Eligible patients had measurable disease, GOG performance status 0-2, and adequate bone marrow, renal, and hepatic function according to standard criteria.
  • RESULTS: Forty-one patients were registered, of whom 4 were determined ineligible (wrong cell type, 2; wrong site of origin, 1; inadequate pathology material, 1).
  • Despite its low therapeutic index, this novel, possibly interactive, combination may serve as a forerunner to regimens that more efficiently exploit the enhancement of sarcoma cell kill under hypoxic conditions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma / drug therapy. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; MAP protocol
  •  go-up   go-down


20. Melichar B, Voboril Z, Nozicka J, Cerman J Jr, Melicharová K, Mergancová J, Filip S, Krajina A, Voboril R, Jandík P: Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases. Tumori; 2005 Jan-Feb;91(1):19-23
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy in sarcoma liver metastases: a report of 6 cases.
  • AIMS AND BACKGROUND: Liver metastases in patients with sarcoma are rare and associated with a poor prognosis.
  • The experience with liver-directed therapies, eg hepatic arterial infusion, in these patients is limited.
  • METHODS: Six patients with sarcoma metastatic to the liver (4 patients with gastrointestinal stromal tumors and 2 patients with leiomyosarcoma) were treated by hepatic arterial infusion in our center over a 12-year period.
  • RESULTS: None of the 5 assessable patients responded to the therapy, and liver metastases progressed in all patients.
  • CONCLUSIONS: Hepatic arterial infusion has little efficacy in the treatment of sarcoma metastatic to the liver.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatic Artery. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Sarcoma / drug therapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intra-Arterial. Jejunal Neoplasms / pathology. Male. Middle Aged. Rectal Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850000.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Poggio JL, Nagorney DM, Nascimento AG, Rowland C, Kay P, Young RM, Donohue JH: Surgical treatment of adult primary hepatic sarcoma. Br J Surg; 2000 Nov;87(11):1500-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of adult primary hepatic sarcoma.
  • BACKGROUND: Primary sarcomas of the liver are extremely rare in adults.
  • Optimal therapeutic approaches remain unclear.
  • METHODS: Twenty consecutive adult patients who had surgical treatment for primary hepatic sarcomas were reviewed.
  • Other than one patient with primary hepatic angiosarcoma who had a history of thorium dioxide colloid (Thorotrast) exposure 23 years before diagnosis, no predisposing causes were apparent.
  • Nineteen patients had hepatic resection and one patient had an orthotopic liver transplant.
  • No patient received neoadjuvant chemotherapy or radiotherapy but radiotherapy was delivered intraoperatively in one patient.
  • RESULTS: Leiomyosarcoma was the most common histological type of sarcoma diagnosed (five of 20 patients), followed by malignant solitary fibrous tumour (four) and epithelioid haemangioendothelioma (three).
  • Thirteen patients developed a recurrence.
  • Distant metastases (ten patients) and intrahepatic recurrence (six) were the predominant sites of initial treatment failure.
  • Six patients received salvage chemotherapy.
  • CONCLUSION: Surgical resection is the only effective therapy for primary hepatic sarcomas at present.
  • Better adjuvant therapy is necessary, especially for high-grade malignancies, owing to the high failure rate with operation alone.
  • [MeSH-major] Liver Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Preoperative Care / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11091236.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Rogiers X, Brunken C: Surgical management of hepatic metastatic disease. Saudi Med J; 2000 Jun;21(6):519-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of hepatic metastatic disease.
  • In Europe, liver metastases are the most common malignomas of the liver.
  • Radical surgical resection, if possible, is the treatment of choice.
  • Radical resection of metastases from wilms-tumor, carcinoids, carcinoma of the breast, hypernephroma, adrenal tumors, malignant melanoma, leiomyosarcoma and gastric cancer may improve long time survival, however knowledge is too small for giving general directions.
  • Local destructive therapies are only beneficial when a total necrosis of the tumor is reached.
  • Indications for this treatment are quite rare.
  • Both, systemic and local chemotherapy offers only palliation with little influence on long time survival.
  • Adjuvant and neo-adjuvant chemotherapy is applicated under study conditions with encouraging results.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / pathology. Europe / epidemiology. Humans. Patient Selection. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11508246.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 17
  •  go-up   go-down


23. Turken O, Basekim C, Haholu A, Karagoz B, Bilgi O, Ozgun A, Kucukardali Y, Narin Y, Yazgan Y, Kandemir EG: Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma. Med Oncol; 2009;26(3):309-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma.
  • Computed tomography (CT) of the abdomen showed multiple hepatic nodular lesions in the liver.
  • The patient received sandostatin treatment.
  • After the treatment with L-ornithine-L-aspartate, a remarkable improvement in the level of patient's sensorium occurred as well as a reduction in serum ammonia level within a few days.
  • There are case reports of hyperammonemia with some malignancies such as multiple myeloma, plasma cell leukemia, and leiomyosarcoma, or in some patients who have received chemotherapy.
  • [MeSH-major] Brain Diseases / blood. Carcinoma, Neuroendocrine / blood. Hyperammonemia / etiology. Liver Neoplasms / blood

  • Genetic Alliance. consumer health - Hepatic encephalopathy.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rinsho Ketsueki. 1998 Jan;39(1):27-33 [9492550.001]
  • [Cites] Anticancer Drugs. 1999 Mar;10(3):275-81 [10327032.001]
  • [Cites] Gan To Kagaku Ryoho. 1998 Nov;25(13):2127-30 [9838918.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):5022-5 [15611524.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S51-61 [11762353.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1220-5 [11193443.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):343-5 [10967577.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2002 May 10;91(5):1589-92 [12082752.001]
  • [Cites] Dig Dis Sci. 2003 Apr;48(4):821-3 [12741478.001]
  • [Cites] Indian J Med Sci. 2005 Jan;59(1):24-7 [15681889.001]
  • [Cites] Chest. 2007 Oct;132(4):1368-78 [17934124.001]
  • [Cites] J Pediatr. 1990 Dec;117(6):897-902 [2246687.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2000 Jul 10;89(7):1433-4 [10934775.001]
  • [Cites] N Engl J Med. 2002 May 23;346(21):1674-5 [12024007.001]
  • [Cites] Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):446-8 [9851186.001]
  • [Cites] Am J Emerg Med. 2004 Mar;22(2):105-7 [15011224.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):139-41 [14968586.001]
  • [Cites] Am J Med. 2004 Feb 1;116(3):210-1 [14749172.001]
  • [Cites] Abdom Imaging. 2004 Nov-Dec;29(6):696-702 [15162235.001]
  • [Cites] Jpn J Clin Oncol. 2001 Dec;31(12):605-9 [11902492.001]
  • [Cites] Eur J Nucl Med. 1993 Apr;20(4):283-92 [8491220.001]
  • (PMID = 19031017.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Serralta AS, Sanjuan FR, Moya AH, Orbis FC, López-Andújar R, Pareja EI, Vila JC, Rayón M, Juan MB, Mir JP: Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol; 2004 Nov;16(11):1237-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours.
  • Therapeutic options for treating unresectable hepatic metastases of leiomyosarcomas were scarce until a few years ago.
  • The introduction of imatinib (an antineoplasic drug that specifically acts on the pathogenesis of these tumours) has shown promising results in patients with advanced GISTs.
  • We present three patients with the initial diagnosis of unresectable hepatic metastases of leiomyosarcomas.
  • They received liver transplants.
  • Histological re-evaluation identified a stromal origin of the tumours, and the patients were treated with imatinib therapy (400 mg/day).
  • Recurrence occurred in all patients after a mean of 38.3 months, but imatinib treatment achieved control of the tumours.
  • The current survival times with the combination of transplantation and imatinib are 92, 48 and 46 months for the three patients.
  • This series is small and inconclusive, but imatinib treatment showed promising results.
  • The treatment options for patients with unresectable metastases of GISTs must be defined, as in these three patients liver transplantation achieved a disease-free status but all had tumour recurrences before starting the imatinib treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leiomyosarcoma / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Combined Modality Therapy / methods. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15489588.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


25. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Diagnostic investigation presented a cerebral, pulmonary, cutaneous, hepatic and pleural metastatic disease.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Almogy G, Lieberman S, Gips M, Pappo O, Edden Y, Jurim O, Simon Slasky B, Uzieli B, Eid A: Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol; 2004 May;30(4):421-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre.
  • BACKGROUND: Primary hepatic sarcoma is a rare tumour with a poor prognosis.
  • METHODS: From 1997 to 2002 eight patients had liver resection for primary sarcoma of the liver at our institution.
  • The clinical characteristics, imaging findings, surgical procedures, adjuvant therapy and outcome were retrospectively reviewed.
  • There were two patients each with angiosarcoma (AS), leiomyosarcoma (LMS), and undifferentiated embryonal sarcoma (UES), one patient with epithelioid hemangioendothelioma (EHE) and one patient with malignant peripheral nerve sheath sarcoma (PNSS).
  • Preoperative diagnosis of a primary liver sarcoma was made in 7/8 cases, either by fine needle aspiration (n = 5) or angiography (n = 2).
  • Two patients developed complications and there was one death.
  • Systemic chemotherapy led to tumour regression in both patients with UES which enabled a second hepatic resection.
  • CONCLUSIONS: The majority of patients with primary liver sarcoma present with right upper quadrant pain, fever and a liver mass.
  • Differentiating the rare primary liver sarcoma from the much more common hepatocellular carcinoma (HCC) may aid in planning therapy.
  • Liver resection combined with adjuvant chemotherapy are the mainstays of treatment for UES in the adult.
  • [MeSH-major] Liver Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Hepatectomy / methods. Humans. Length of Stay. Liver Function Tests. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15063896.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006 Jun;141(6):537-43; discussion 543-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.
  • HYPOTHESIS: A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation.
  • PATIENTS AND METHODS: Sixty-six patients who underwent hepatic resection and/or open radiofrequency ablation of metastatic sarcoma between July 1, 1996, and April 30, 2005, were identified from the database.
  • Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12).
  • Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival.
  • CONCLUSIONS: Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor.
  • Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.
  • [MeSH-major] Catheter Ablation. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Neoplasms / pathology. Disease-Free Survival. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Casper ES: Gastrointestinal stromal tumors. Curr Treat Options Oncol; 2000 Aug;1(3):267-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms.
  • Both benign and malignant types are recognized.
  • Complete en bloc surgical resection, when possible, is the cornerstone of therapy.
  • Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon.
  • For patients with unresectable disease, the results with systemic chemotherapy have been dismal.
  • Treatment with doxorubicin/ifosfamide combinations is of dubious value.
  • Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients.
  • The impact of such treatment on outcome, however, is poorly studied.
  • Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Humans. Radiotherapy. Stromal Cells / pathology. Survival Rate

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):926-32 [2067035.001]
  • [Cites] Ultrastruct Pathol. 1996 Jul-Aug;20(4):373-93 [8837346.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2083-8 [7697597.001]
  • [Cites] Radiographics. 1998 Mar-Apr;18(2):379-92 [9536485.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):413-9 [10448292.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):887-97 [8394653.001]
  • [Cites] Am J Surg Pathol. 1986;10 Suppl 1:83-99 [3296804.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1633-6 [9881963.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):287-90 [9891767.001]
  • [Cites] N Engl J Med. 1993 Apr 15;328(15):1107-14 [8455669.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):126-31 [2491883.001]
  • [Cites] Gastrointest Endosc. 1997 Jun;45(6):468-73 [9199902.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] J Allergy Clin Immunol. 1997 Oct;100(4):435-40 [9338533.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • (PMID = 12057170.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


29. Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer; 2003 Sep;39(13):1842-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One pCR (melanoma), CR (uterine leiomyosarcoma), one PR (colon stromal sarcoma) and a MR (37% tumour shrinkage, gastric stromal sarcoma) were observed.
  • A further 9 patients with colorectal, mesothelioma, bile duct carcinoma and bladder cancer had SD which lasted for six or more treatment cycles.
  • The haematological and hepatic toxicities of ET-743 were dose-dependent and not cumulative.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacokinetics. Dioxoles / pharmacokinetics. Isoquinolines / pharmacokinetics. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Tetrahydroisoquinolines

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12932661.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down






Advertisement